Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GPC3-targeted plasmid DNA vaccine NWRD06

A plasmid DNA therapeutic cancer vaccine encoding glypican-3 (GPC3), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of GPC3-targeted plasmid DNA vaccine NWRD06 and following electroporation, the plasmids enter the cells, and the cells express GPC3 and elicit a GPC3-specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing GPC3. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:NWRD 06
NWRD-06
NWRD06
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search